European Urology Oncology
Издатель: Elsevier · ISSN 2588-9311 · 84 статей
- Contents
- Hall of Fame
- The Price of Cure: Rethinking Success in High-risk Prostate Cancer
- Patient Selection Matters: Who Is Represented in PROTEUS?
- Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathways
- Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E
- Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials
- Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel
- Feasibility and Characterization of Immune-related Pathologic Response Criteria in Renal Cell Carcinoma
- Multiregional Immune Profiling Reveals Prognostic Patterns in Bladder Cancer
- Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer
- Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy
- Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study)
- MRI Quality and Reader Experience in Organized Prostate Cancer Screening: Insights from the PROBASE Trial
- Head-to-head Comparison of Multimodal Imaging for Prostate Cancer Detection and Local Staging with Whole-mount Histopathology Reference
- Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials
- Quality of Life After Postprostatectomy Radiotherapy: A TROG 08.03 RAVES Randomized Controlled Trial Substudy
- Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort
- Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics
- Natural History, Tumor Growth Kinetics, and Renal Functional Outcomes of Sporadic Bilateral Multifocal Papillary Renal Cell Carcinoma: A 25-yr Prospective Cohort Study
- Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review
- Re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404–412
- Reply to Pietro Scilipoti, Giuseppe Rosiello, Andrea Salonia, Alberto Briganti, Marco Moschini, Francesco Montorsi Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404–12
- Re: Parizi MK, D’Andrea D, Pradere B, et al. Prognostic factors for recurrence and survival after radical cystectomy for non-muscle invasive bladder cancer: a multicenter analysis of 1032 patients. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.06.001: Prognostic Factors After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: From Prognostication to Patient Selection
- Reply to Simone Sforza’s Letter to the Editor re: Mehdi Kardoust Parizi, David D’Andrea, Benjamin Pradere, et al. Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients. In press. http://dx.doi.org/10.1016/j.euo.2026.06.001
- Re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non–muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9:652–9
- Reply to Roberto M. Scarpa’s Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non–muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652–9
- Re: Stacy Loeb, Mariana Rangel Camacho, Tatiana Sanchez Nolasco, et al. Downstream Impact of Social Media Use and Variable Quality of Online Information About Prostate Cancer. Eur Urol Oncol 2025;8:1648–52
- Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008
- Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial